Literature DB >> 15203091

Catalytic antioxidants: a radical approach to new therapeutics.

Brian J Day1.   

Abstract

In humans, several pathologies involve the overproduction of reactive oxygen species. Metal-containing catalytic antioxidants have emerged as a novel class of potential therapeutic agents that scavenge a wide range of reactive oxygen species. There are three structural classes of manganese-containing catalytic antioxidants that have efficacy in several oxidative stress models of human disease. The classes are divided based on their in vitro selectivity towards the scavenging of superoxide. The selective catalytic antioxidants include the macrocyclics, whereas the non-selective catalytic antioxidants include the salens and porphyrins. Cardiovascular, neurodegenerative and inflammatory lung disorders are all potentially important targets for catalytic antioxidant therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203091     DOI: 10.1016/S1359-6446(04)03139-3

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  54 in total

1.  Stability, disposition, and penetration of catalytic antioxidants Mn-porphyrin and Mn-salen and of methylprednisolone in spinal cord injury.

Authors:  Liqin Wu; Yichu Shan; Danxia Liu
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-06

2.  Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease.

Authors:  Li-Ping Liang; Jie Huang; Ruth Fulton; Jennifer N Pearson-Smith; Brian J Day; Manisha Patel
Journal:  Toxicol Appl Pharmacol       Date:  2017-04-08       Impact factor: 4.219

3.  Antioxidants used by Deinococcus radiodurans and implications for antioxidant drug discovery.

Authors:  Hong-Yu Zhang; Xue-Juan Li; Na Gao; Ling-Ling Chen
Journal:  Nat Rev Microbiol       Date:  2009-06       Impact factor: 60.633

Review 4.  Antioxidants as potential medical countermeasures for chemical warfare agents and toxic industrial chemicals.

Authors:  Cameron S McElroy; Brian J Day
Journal:  Biochem Pharmacol       Date:  2015-10-22       Impact factor: 5.858

Review 5.  Targeting Oxidative Stress in Central Nervous System Disorders.

Authors:  Manisha Patel
Journal:  Trends Pharmacol Sci       Date:  2016-08-01       Impact factor: 14.819

6.  A manganese-porphyrin complex decomposes H(2)O(2), inhibits apoptosis, and acts as a radiation mitigator in vivo.

Authors:  Detcho A Stoyanovsky; Zhentai Huang; Jianfei Jiang; Natalia A Belikova; Vladimir Tyurin; Michael W Epperly; Joel S Greenberger; Hülya Bayir; Valerian E Kagan
Journal:  ACS Med Chem Lett       Date:  2011-11-10       Impact factor: 4.345

Review 7.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 8.  Extracellular superoxide dismutase in pulmonary fibrosis.

Authors:  Fei Gao; Vuokko L Kinnula; Marjukka Myllärniemi; Tim D Oury
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

9.  Catalytic antioxidant AEOL 10150 treatment ameliorates sulfur mustard analog 2-chloroethyl ethyl sulfide-associated cutaneous toxic effects.

Authors:  Neera Tewari-Singh; Swetha Inturi; Anil K Jain; Chapla Agarwal; David J Orlicky; Carl W White; Rajesh Agarwal; Brian J Day
Journal:  Free Radic Biol Med       Date:  2014-05-09       Impact factor: 7.376

10.  Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.

Authors:  Phyllis Chew; Derek Y C Yuen; Nada Stefanovic; Josefa Pete; Melinda T Coughlan; Karin A Jandeleit-Dahm; Merlin C Thomas; Franklin Rosenfeldt; Mark E Cooper; Judy B de Haan
Journal:  Diabetes       Date:  2010-09-07       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.